Finovam Gestion

Finovam Gestion focuses on seed and early-stage rounds — specifically, the first institutional equity raises for technology startups. The firm positions itself as the initial external backer before traditional venture funds participate, a role it describes as investing in 'les premiers tours de tables et les premières levées de fonds' (per firm website). Its portfolio companies include pre-revenue biotech and deep-tech startups, consistent with pre-Series A deployment.

Confirmed portfolio companies span neurodegenerative disease therapeutics (AlzProtect), sodium-ion battery technology (Tiamat), and enterprise cybersecurity (Oversoc) — all detailed on the firm's website. This concentration suggests a thematic preference for life sciences, energy transition, and cybersecurity, each grounded in significant patentable or regulatory-barrier innovations.

The firm maintains offices in Lille, Metz, Amiens, and Dijon — a regional network that deviates from the Paris-centric sourcing model common among French venture managers. This four-city presence in northern and eastern France gives Finovam proximity to university spinouts and engineering-school labs, the primary origin points for the deep-tech companies that characterize its portfolio.

Finovam Gestion is structured as an independent asset manager, not a family office. It operates as a private equity firm raising and deploying third-party or proprietary capital into early-stage companies. No wealth-origin disclosure, named principals, or beneficial-owner information is publicly available, which is consistent with a private investment firm rather than a vehicle for a single family's capital.

There is no public disclosure of fund-of-fund commitments, co-investment vehicles, or SPVs. Finovam's website presents only direct portfolio company holdings, suggesting the firm operates through direct equity investments rather than aggregating commitments to other GPs.